; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
"https://www.domainregistry.de/eu.html" target="_new">https://www.domainregistry.de/eu.
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
html).
Sunrise Period
You should send now to your applications to secure your ri
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
hts at the new eu-domains. The eu-domains will be the most important event since the in
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
roduction of com-domains.
There will be a Sunrise Period (Phased registration for thos
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
e holding prior rights to a name) at the eu-domains.
The Sunrise Period of eu-domains
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ill have two phases:
The EU Regulation stipulates that the registry must make a sunris
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
e provision at eu-domains to allow those with 'prior rights' to a name to apply for reg
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
stration of eu-domains in advance of beginning general registrations. The PPR states th
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
t the sunrise period (phased registration) of eu-domains will take place in two phases
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
each lasting two months.
During phase one, public bodies and holders of registered Com
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
unity or national trademarks will be able to register their names.
During phase 2 thos
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
e who may register in phase 1 may register their eu-domains as well holders of other ri
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
hts recognised under Community law or the national law of an EU member state. Eu-domain
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
registered during the sunrise period must be an exact match for the prior right claime
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
d and documentary evidence must be supplied to proof the right.
Live Registration: Fir
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
t comes-first serves
Some weeks after the Sunrise Period eu-domains goes live and gene
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
ral registrations of eu-domains will begin and registration of eu-domains will be done
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
n a first come first served basis for any eu-domain not taken during the sunrise period
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
